Psychopharmacotherapy of Schizophrenia with Long-Acting Antipsychotic Drugs in the Context of Expansion of Hospital-Substituting Forms of Psychiatric Care

Background: the main goals of schizophrenia spectrum disorders therapy include not only achieving clinical improvement, but also the restoration of social functioning. This is especially relevant in light of the biopsychosocial concept of the development of this disease, which necessitates an integrated approach to considering its etiopathogenetic and therapeutic aspects. The main treatment and rehabilitation work with patients at the current stage of development of practical healthcare is carried out on an outpatient basis. This is facilitated by the reform of the psychiatric service with the reduction of the inpatient unit and the development of inpatient-substituting forms of mental health care. The aim of review was to analyze the scientific publications on the development of psychiatric care for schizophrenia spectrum disorders in outpatient settings. Material and Methods: using keywords “schizophrenia”, “outpatient care”, “long acting injectable antipsychotics” the source of articles on the possibilities of using long-acting antipsychotic drugs to improve compliance with the therapeutic regimen and prevent psychotic relapse was carried out in PUBMED, e-library and other bases for 10 years. The positive and negative aspects of the use of deposited dosage forms at the stage of maintenance antipsychotic therapy are considered. Additional psychosocial therapies are discussed as part of an integrated approach to treating patients with schizophrenia. Conclusion: the results of the review allow us to conclude that there is a need to develop pharmacological and psychosocial treatment of schizophrenia at the outpatient stage, with an emphasis on anti-relapse maintenance therapy and concomitant social rehabilitation.

1. Gurovich IYa, Storozhakova YaA, Foursov BB. Interna tional experience of psychiatric reform and further development of the Russian psychiatric care. Social and Clinical Psychiatry. 2012;22(1):5–19. (In Russ.).

2. Shmukler AB, Gurovich IYa, Kostyuk GP. Inpatient psychiatric care: deinstitutionalization and its con sequences in Northern America and Europe. Social and Clinical Psychiatry. 2016;26(4):97–109. (In Russ.).

3. Gurovich IYa, Shmukler AB, Kostyuk GP, Naryshkin AV. The patient population with schizophrenia and schizophrenia spectrum disorders treated in a psy chiatric hospital (according to one-day assessment data) Social and Clinical Psychiatry 2013;23(3):54–60. (In Russ.).

4. Krupchanka DA, Simonian VG. Issues of Health Care Provision for People Suffering from Schizophrenia. Difficult patient. 2015;3:49–56. (In Russ.).

5. Dutov VB, Neznanov NG, Sofronov AG, et al. A vision for the developmentof mental health care centers. Social and Clinical Psychiatry. 2018;28(4):54–60. (In Russ.).

6. Shenderov KV, Kostyuk GP, Vinidiktova GI, Gu kasyan E.O., Kurilovich, E.A., Lapshin A.O., Petrukh ina N.S. Characteristics of population and phar macotherapy of patients with schizophrenia and schizophrenia spectrum disorders in day clinics by psychoneurological dispensaries (based on the ma terials of the Ghilyarovsky psychiatric hospital nr. 3). Social and Clinical Psychiatry. 2016;26(1):59–68. (In Russ.).

7. Marwaha S, Johnson S. Schizophrenia and employ ment — a review. Soc Psychiatry Psychiatr Epidemiol. 2004;39(5):337–49. doi: 10.1007/s00127-004-0762-4 PMID: 15133589.

8. Shaposhnikov NN, Sitchikhin PV. Dynamics and cor relations of disability of adult population owing to schizophrenia with basic indicators of activity of mental health service. Kuban Scientific Medical Bulle tin. 2016;6:140–145. (In Russ.). doi: 10.25207/1608-6228-2016-6-140-145

9. Rahimov KD, Akimbaeva AM, Zordinova KA, Gulam ova GM. Evident pharmacotherapy of schizophrenia (clinical and epidemiological aspects) Modern prob lems of science and education. 2010;4:137–156. (In Russ.).

10. Bukreeva ND, Azaeva GD, Sorokina VA. Organizational aspects of building up commitment to management of psychiatric patients. The Russian Journal of Psy chiatry. 2012;1:13–20. (In Russ.).

11. Lyubov EB, Bessonova AA. First-episode of schizo phrenia: clinico-epidemiological and socio-eco nomic aspects. The Russian Journal of Psychiatry. 2008;2:46–50. (In Russ.).

12. Sreeraj VS, Shivakumar V, Rao NP, Venkatasubra manian G. Long-acting drug delivery systems for schizophrenia treatment In: Woodhead Publishing Series in Biomaterials. Long-Acting Drug Delivery Systems. Woodhead Publishing, 2022. Р. 203–222. doi: 10.1016/B978-0-12-821749-8.00009-4

13. Berezantsev AYu, Kostyuk GP, Burygina LA, Levin ME, Masyakin AV. The new stage in the development of a system for the treatment and rehabilitation of pa tients with schizophrenic spectrum disorders. Health care of the Russian Federation. 2020;64(4):181–189. (In Russ.). doi: 10.46563/0044-197X-2020-64-4-181-189

14. Shukil LV, Cheperin AI, Sheller AD, Volchkova TF. Psy chiatric care in the Omsk region. Social and Clinical Psychiatry. 2016;4:39–48. (In Russ.).

15. Ushakov YV, Kravchenko NE, Suetin ME. To the prob lem of assessing the quality of outpatient medical care for patients with schizophrenia in the daily practice of the district psychiatrist. Current Therapy of Mental Disorders. 2018;(3–4):4–7. (In Russ.).

16. Kostyuk GP, Masyakin AV. Analysis of the resource provision of medical organizations providing assis tance in the stationary conditions for the psychia try Moscow profile. Current problems of health care and medical statistics. 2019;2:313–322. (In Russ.). doi: 10.24411/2312-2935-2019-00045

17. Zolotareva LS, Masyakin AV. Improving the system of organizing the psychiatric aid of the megapolis. Manager Zdravoochranenia. 2019;7:23–29. (In Russ.).

18. Masyakin AV. Results on sociological survey of healthcare specialists and consumers about their opinion on reforms of psychiatric service in Mos cow, conducted in 2010-2017. Medical Technologies. Assess ment and Choice. 2019;2(36):49–58. (In Russ.). doi: 10.31556/2219-0678.2019.36.2.049-058

19. Gurovich IYa, Shmukler AB, Storozhakova YaA. Psiho social’naja terapija i psihosocial’naja reabilitacija v psihiatrii. Moscow: Medpraktika, 2004. (In Russ.).

20. Shashkova NG, Kiryanova EM, Salnikova LI, Storozha kova YaA. Alterations with schizophrenia and schizo phrenia spectrum disorders outpatient populations and current situation with dispensary observation. Social and Clinical Psychiatry. 2018;28(1):36–43. (In Russ.).

21. Shashkova NG, Semyonova ND. Patients with schizo phrenia and schizophrenia spectrum disorder that refuse outpatient guidance and treatment. Social and Clinical Psychiatry. 2019;29(1):24–31 (In Russ.).

22. Vilyum IA, Andreev BV Proskurin MA, Balykina YuE. Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia. FAR MAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2018;11(1):3–18. (In Russ.) doi: 10.17749/2070-4909.2018.11.1.003-018

23. Choon JWY, Wu DBC, Chong HY, Lo WTL, Chong CSY, Chung WS, Chui EMC, Tomlinson B, Lee VWY, Lee SC, Lee KKC. Real-world evidence of improved healthcare utilization in patients with schizophrenia or schi zoaffective disorder after early treatment of pali peridone palmitate once-monthly treatment in Hong Kong. J Med Econ. 2019;22(3):273–279. doi: 10.1080/13696998.2018.1560749 Epub 2019 Jan 14. PMID: 30561238.

24. Belostotskiy AV, Ter-Israelyan AYu, Evdokimova TE. Current issues of the organization and rendering of psychiatric aid in modern conditions. Bulletin of Semashko National Research Institute of Public Health 2019;2:12–21. (In Russ.). doi: 10.25742/NRIPH.2019.02.002

25. Chumakov EM. Current non-pharmacological and pharmacological treatment strategies for schizo phrenia aimed at improving compliance. Current Ther apy of Mental Disorders. 2022;3:58–66. (In Russ.). doi: 10.21265/PSYPH.2022.97.90.007

26. Brissos S, Veguilla MR, Taylor D, Balanzá-Martínez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic ad vances in psychopharmacology. 2014;4(5):198–219. doi: 10.1177/2045125314540297

27. Correll CU, Kim E, Sliwa JK, Hamm W, Gopal S, Mathews M, Venkatasubramanian R, Saklad SR. Phar macokinetic Characteristics of Long-Acting Inject able Antipsychotics for Schizophrenia: An Overview. CNS Drugs. 2021 Jan;35(1):39–59. doi: 10.1007/s40263-020-00779-5 Epub 2021 Jan

28. Erratum in: CNS Drugs. 2025 Jan;39(1):111–112. doi: 10.1007/s40263-024-01138-4 PMID: 33507525; PMCID: PMC7873121.

29. García S, Martínez-Cengotitabengoa M, López-Zurba no S, Zorrilla I, López P, Vieta E, González-Pinto A. Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review. J Clin Psychopharmacol. 2016 Aug;36(4):355 71. doi: 10.1097/JCP.0000000000000523 PMID: 27307187; PMCID: PMC4932152.

30. Patel MX, David AS. Why aren’t depot antipsychotics prescribed more often and what can be done about it? Advances in psychiatric treatment. 2005;11(3):203 211. doi: 10.1192/apt.11.3.203

31. Gerlach J. Depot neuroleptics in relapse pre vention: advantages and disadvantages. Int Clin Psychopharmacol. 1995 Jan;9 Suppl 5:17-20. doi: 10.1097/00004850-199501005-00004 PMID: 7622829.

32. Heres S, Lambert M, Vauth R. Treatment of early epi sode in patients with schizophrenia: the role of long acting antipsychotics. Eur Psychiatry. 2014;29 Suppl 2:1409–13. doi: 10.1016/S0924-9338(14)70001-X Epub 2014 Nov 22. PMID: 25455704.

33. Pae CU, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS. Consideration of Long-Acting Injectable Antipsy chotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not? Clin Psychopharmacol Neurosci. 2021;19(3):434–448. doi: 10.9758/cpn.2021.19.3.434 PMID: 34294613; PMCID: PMC8316655.

34. Remington GJ, Adams ME. Depot neuroleptic therapy: clinical considerations. Can J Psychiatry. 1995;40(3 Suppl 1):S5-11. PMID: 7627927.

35. Russian Society of Psychiatrists. Shizofrenija. Klinicheskie rekomendacii. Moscow, 2021. Available from: https://cr.minzdrav.gov.ru/recomend/451_2. (In Russ.).

36. Weiden PJ. Redefining Medication Adherence in the Treatment of Schizophrenia: How Current Ap proaches to Adherence Lead to Misinformation and Threaten Therapeutic Relationships. Psychiatr Clin North Am. 2016;39(2):199–216. doi: 10.1016/j.psc.2016.01.004 Epub 2016 Mar 10. PMID: 27216900.

37. Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adher ence and clinical, functional, and economic out comes of schizophrenia. Patient Prefer Adherence. 2013;7:1171–1180. doi: 10.2147/PPA.S53795 PMID: 24265549; PMCID: PMC3833623.

38. Tarakanova EA, Kozhanov AV. Current psychotherapy of schizophrenia: saving the lives of patients. Bul letin of the Academy of Knowledge. 2015;12(1):120 125. (In Russ.).

39. Danilov DS. Therapeutic collaboration of schizo phrenic patients and a physician (the significance for therapeutic efficiency, the mechanisms of for mation, and correction methods). Neurology, Neu ropsychiatry, Psychosomatics. 2011;(2):17–24. (In Russ.).

40. Yalçin N, Ak S, Gürel ŞC, Çeliker A. Compliance in schizo phrenia spectrum disorders: the role of clinical phar macist. Int Clin Psychopharmacol. 2019;34(6):298 304. doi: 10.1097/YIC.0000000000000280 PMID: 31343497.

41. Song X, El Khoury AC, Brouillette M, Smith D, Joshi K. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia. J Med Econ. 2019;22(11):1105–1112. doi: 10.1080/13696998.2019.1615927 Epub 2019 May 23. PMID: 31062998.

42. Mursalova Z. To Whom We Prescribe Long Acting Antpsychotics at Discharge from Hospital? Schizophr Bull. 2020;46:216.

43. Mosolov S, Tsukarzi E, Alfimov P. Algorithms for bio logical treatment of schizoprenia. Current Therapy of Mental Disorders. 2014;(1):27–36. (In Russ.).

44. Devrımcı Özgüven H, Kir Y. Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder. Noro Psikiyatr Ars. 2021;58(Sup pl 1):S47–S52. doi: 10.29399/npa.27480 PMID: 34658635; PMCID: PMC8498817

45. Stevens GL, Dawson G, Zummo J. Clinical benefits and impact of early use of long-acting injectable anti psychotics for schizophrenia. Early Interv Psychia try. 2016;10(5):365–77. doi: 10.1111/eip.12278 Epub 2015 Sep 25. PMID: 26403538; PMCID: PMC5054869.

46. Lyubov EB. Long-acting injectable antipsychotics in the first-episode schizophrenia: a clinical perspective (analytical review). The Russian Journal of Psychia try. 2013;(6):59–69. (In Russ.). doi: 10.24411/1560 957X-2013-11377

47. Patel C, Emond B, Morrison L, Lafeuille MH, Lefebvre P, Lin D, Kim E, Joshi K. Risk of subsequent relapses and corresponding healthcare costs among recent ly-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study. Curr Med Res Opin. 2021;37(4):665–674. doi: 10.1080/03007995.20 21.1882977 Epub 2021 Feb 14. PMID: 33507831.

48. Hong J, Novick D, Brugnoli R, Bertsch J, Haro JM. Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizo phrenia. Hum Psychopharmacol. 2013;28(5):438–46. doi: 10.1002/hup.2328 Epub 2013 Jun 15. PMID: 23775950.

49. Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry Suppl. 2009;52:S13-9. doi: 10.1192/bjp.195.52.s13 PMID: 19880912.

50. Oleneva EV, Kapiletti SG, Ryvkin PV, Ladyzhenskii MJ. Rispolept Consta — 10 years of practice in Russia: some conclusions. Current Therapy of Mental Disor ders. 2015;(1):10–24. (In Russ.).

51. Fusar-Poli P, Kempton MJ, Rosenheck RA. Effi cacy and safety of second-generation long-act ing injections in schizophrenia: a meta-analy sis of randomized-controlled trials. Int Clin Psy chopharmacol. 2013;28(2):57–66. doi: 10.1097/ YIC.0b013e32835b091f PMID: 23165366.

52. Sampogna G, Del Vecchio V, De Rosa C, Giallonardo V, Luciano M, Palummo C, Di Vincenzo M, Fiorillo A. Community Mental Health Services in Italy. Consort Psychiatr. 2021;2(2):86–92. doi: 10.17816/CP76 PMID: 39070729; PMCID: PMC11272313.

53. Oleneva EV, Ryvkin PV, Ladyzhensky MYa. Potential of paliperidone palmitate in long-term preventing therapy of relapses in schizophrenia (review of evi dence-based studies). Current Therapy of Mental Dis orders. 2018;(1):37–44. (In Russ.). doi: 10.21265/ PSYPH.2018.44.11529

54. Sivolap JuP., Portnova AA, Janushkevich MV, Savchen kov VA, Pushin PV. Schizofrenia as an object of com petence of psychiatrist, narcologist, cardiologist, endocrinologist and pathologist. Neurology bulletin. 2020;52(3):76–81. (In Russ.). doi: 10.17816/nb44729

55. Shvets KN, Khamskaya IS. Factors of social disadapta tion of patients with schizophrenia and approaches to psychosocial therapy and rehabilitation (review). Research Results in Biomedicine. 2019;5(2):72–85. (In Russ.). doi: 10.18413/2658-6533-2019-5-2-0-8

56. Sofronov AG, Spikina AA, Saveljev AP, Parfenov JuA. Analysis of the results of long-term supporting therapy of schizophrenia. V.M. Bekhterev review of psychiatry and medical psychology. 2013;1(1):101 113. (In Russ.).

57. Bochkaryova OS. The dynamics and long-term out come in schizophrenia and schizophrenia spectrum disorder in patient subgroups with different course of disease. Social and Clinical Psychiatry. 2018;28(3):18 22. (In Russ.).

58. Shmukler AB. On the issue of the reorganization of the psychiatric service. Social and Clinical Psychiatry. 2021;31(3):91–95. (In Russ.).

59. Samojlova DD, Baryl’nik JuB, Janushko PS. Psihoo brazovanie kak sostavljajushhaja processa psihore abilitacii pacientov s shizofreniej. Bulletin of Medical Internet Conferences. 2015;5(2):104–107. (In Russ.).

60. Vid VD, Lutova NB. The evidence-based psychother apy of psychoses: current analysis of the problem. V.M. Bekhterev review of psychiatry and medical psycho logy. 2019;4:12–16. (In Russ.). doi: 10.31363/2313 7053-2018-4-12-16

61. Osokina OI. The possibility of drug treatment and psychotherapy in potentiation of remission in pa tients with early stages of schizophrenia. Inter national neurological journal. 2015;5(75):116–124. (In Russ.).

62. Ruzhenkaya EV. Sociorehabilitation organization in persons with psychic disorders: modern ap proaches. Bulletin of the Ivanovo Medical Academy. 2016;21(2):10–15. (In Russ.).

63. Shenderov KV, Vinidiktova GI, Kostyuk GP, Mikha lev MA, Belitsin DN, Visnevskaya LYa, Vorobyev AM, Lapshin AO, Petruchina NS, Segreneva-Vorobyeva NM, Shashkova NG. Comparative analysis of patients’ characteristics and treatment and rehabilitation approaches in day program units of a psychoneuro logical dispensary (based on one-day census data). Social and Clinical Psychiatry. 2015;25(1):45–52. (In Russ.).

64. Chien WT, Cheung EFC, Mui JHC, Gray R, Ip G. Adher ence therapy for schizophrenia: a randomised con trolled trial. Hong Kong Med J. 2019;25(1):4–9. PMID: 30674700.

65. Chukanova EK. Effectiveness of comprehensive psy chosocial interventions for patients with schizo phrenia and schizophrenia spectrum disorders in a psychoneurological dispensary. Social and Clinical Psychiatry. 2014;24(1):21–27. (In Russ.).

66. Shenderov KV. Efficacy of multicomponent care for patients with schizophrenia and schizophrenia spectrum disorders in a day clinic of psycho-neu rological dispensary. Social and Clinical Psychiatry. 2010;20(3):54–58. (In Russ.).

67. Sofronov AG, Gritsevskaya TM, Savelyev AP, Kor man TA. Optimization of long-term results of schizophrenia treatment in the long complex thera py with paliperidone palmitate in combination with psychosocial interventions in outpatient settings. Social and Clinical Psychiatry. 2017;27(1):39–47. (In Russ.).

68. Grishina NK, Ter-Israelyan AYu, Evdokimova TE, Za goruychenko AA. To the question of integrating outpatient mental health module providing spe cialized care to patients. Manager Zdravoochranenia. 2020;3:37–43. (In Russ.).

69. Belostotskiy AV, Ter-Israelyan AYu, Grishina NK, Zagoruychenko AA. Aspects of medical rehabilita tion in the reform of psychiatric services. Manager Zdravoochranenia. 2020;1:35–41. (In Russ.).

70. Gurovich IYa. The state of psychiatric care system in Russia: current challenges against background shrinking of the in-patient care. Social and Clinical Psychiatry. 2012;22(4):5–9. (In Russ.).